TABLE 1.
Demographic characteristics of study cohort overall, with obesity, and with diabetes
| Median (IQR) | Overall | Patients with obesity | Patients with diabetes |
|---|---|---|---|
| Demographics | |||
| Age (y) | n=548 | n=359 | n=292 |
| 58 (15) | 57 (15) | 59 (14) | |
| Male sex, N/n (%) | 190/548 (35) | 124/359 (35) | 100/292 (34) |
| BMI (kg/m²) | n=501 | n=359 | n=267 |
| 33.3 (8.5) | 35.7 (7.5) | 33.3 (8.1) | |
| Comorbidities, N/n (%) | |||
| Diabetes | 292/548 (53) | 199/359 (55) | 292/292 (100) |
| Hypertension | 283/547 (52) | 193/359 (54) | 176/292 (60) |
| Obesity | 359/501 (72) | 359/359 (100) | 199/267 (75) |
| Morbid obesity | 99/501 (20) | 99/359 (28) | 53/267 (20) |
| Blood | |||
| AST (IU/L) | n=548 | n=359 | n=292 |
| 36 (30) | 40 (31) | 35 (28) | |
| ALT (IU/L) | n=548 | n=359 | n=292 |
| 44 (42) | 45 (46.5) | 41 (39) | |
| AST/ALT | n=548 | n=359 | n=292 |
| 0.9 (0.4) | 0.8 (0.4) | 0.9 (0.4) | |
| Platelets (1000/uL) | n=548 | n=359 | n=292 |
| 208 (111) | 214 (112) | 204 (102) | |
| HDL (mmol/L) | n=413 | n=264 | n=292 |
| 1.2 (0.4) | 1.2 (0.4) | 1.1 (0.4) | |
| LDL (mmol/L) | n=401 | n=255 | n=209 |
| 2.5 (1.2) | 2.5 (1.2) | 2.4 (1.2) | |
| Albumin (g/L) | n=534 | n=353 | n=287 |
| 44 (4) | 43 (4) | 44 (5) | |
| Bilirubin (µmol/L) | n=547 | n=358 | n=292 |
| 10.3 (6.8) | 9.3 (5.1) | 10.3 (6.8) | |
| Alkaline phosphatase (IU/L) | n=405 | n=272 | n=223 |
| 81 (36) | 82 (37) | 81 (38) | |
| Noninvasive tests | |||
| FIB-4 | n=548 | n=359 | n=292 |
| 1.67 (1.61) | 1.7 (1.5) | 1.7 (1.5) | |
| LSM by VCTE (kPa) | n=548 | n=359 | n=292 |
| 12 (10) | 13 (10) | 12 (10) | |
| Fibrosis, N/n (%) | |||
| NASH | 239/477 (50) | 167/310 (54) | 133/252 (53) |
| Fibrosis stage by Kleiner, N/n (%) | |||
| F0 | 75/548 (14) | 46/359 (13) | 35/292 (12) |
| F1 | 114/548 (21) | 73/359 (20) | 49/292 (17) |
| F2 | 104/548 (19) | 75/359 (21) | 61/292 (21) |
| F3 | 111/548 (20) | 70/359 (20) | 72/292 (25) |
| F4 | 144/548 (26) | 95/359 (27) | 75/292 (26) |
Note: Obesity is defined as BMI ≥30. Morbid obesity is defined as BMI ≥35.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; F0, fibrosis stage 0; F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; FIB-4, fibrosis-4 index; IQR, interquartile range; LSM, liver stiffness measurement; VCTE, vibration-controlled transient elastography.